Cancer of the stomach Book Section
| Authors: | Ku, G. Y.; Ilson, D. H. |
| Editors: | Niederhuber, J. E.; Armitage, J. O.; Kastan, M. B.; Doroshow, J. H.; Tepper, J. E. |
| Article/Chapter Title: | Cancer of the stomach |
| Abstract: | Gastric cancer is a common malignancy globally, although it is uncommon in the United States and Western Europe. Risk factors include Helicobacter pylori infection. Significant advances in the molecular classification of gastric cancer were made by The Cancer Genome Atlas and the Asian Cancer Research Group. Surgery is the mainstay of therapy for localized disease and the addition of perioperative chemotherapy or postoperative chemoradiation has been shown to improve survival for locally advanced tumors. Combination chemotherapy remains the cornerstone of palliative chemotherapy for metastatic or recurrent disease and recent advances include the validation of the anti-Her2 antibody trastuzumab (in the first-line setting with chemotherapy) and the antivascular endothelial growth factor receptor antibody ramucirumab (as second-line therapy with or without chemotherapy). There is also now proven, albeit modest, activity for anti-programmed death-1 antibodies in the chemorefractory setting. © 2020 Elsevier Inc. |
| Keywords: | chemotherapy; radiation; immunotherapy; surgery; gastric cancer |
| Book Title: | Abeloff’s Clinical Oncology. 6th ed |
| ISBN: | 9780323476744 |
| Publisher: | Elsevier Inc. |
| Publication Place: | Philadelphia, PA |
| Date Published: | 2020-01-01 |
| Start Page: | 1197 |
| End Page: | 1210.e3 |
| Language: | English |
| DOI: | 10.1016/b978-0-323-47674-4.00072-4 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book Chapter: 72, part of "Section F: Gastrointestinal" in "Part III: Specific Malignancies" -- Export Date: 1 March 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work